Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

juvenile idiopathic arthritis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

juvenile idiopathic arthritis

MONDO:0011429

Also known as:Arthritis, Juvenile RheumatoidJIAjuvenile rheumatoid arthritis

Find Clinical TrialsTrials

Overview

Juvenile idiopathic arthritis (JIA) is the term used to describe a group of inflammatory articular disorders of unknown cause that begin before the age of 16 and last over 6 weeks. The term juvenile idiopathic arthritis was chosen to signify the absence of any known mechanism underlying the disorder and to highlight the necessity of excluding other types of arthritis occurring in well defined diseases (in particular arthritis occurring in association with infectious, inflammatory and haematooncologic diseases).

Treatments7 FDA approved, newest 2025

Clinical Trials73 registered · 36 recruiting

Diagnosis

Biomarker and diagnostic research for juvenile idiopathic arthritis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

5 FDA-approved treatments are available for juvenile idiopathic arthritis, including ADALIMUMAB (HUMIRA, approved 2002), mobic (MOBIC, approved 2000), and MELOXICAM (MELOXICAM, approved 2004). An additional 10 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: 1-5 in 10,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

73 clinical trials registered, 36 recruiting. Interventions under study include other interventions, drug therapy, and biologic therapy. Pipeline includes 6 PHASE4, 8 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07000916](https://clinicaltrials.gov/study/NCT07000916)

Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:604302

Orphanet

European rare disease database

Orphanet:92

GARD

Genetic and Rare Diseases Info Center

GARD:18677

Questions for Your Care Team

→What are the benefits and potential side effects of HUMIRA for managing juvenile idiopathic arthritis?
→Are any of the 73 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients	protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients	Leonard S. Girsh, MD	2017	—	Designated
Kre-Celazine	Kre-Celazine	All American Pharmaceutical & Natural Foods Corpor	2013	—	Designated
rofecoxib	rofecoxib	MERCK & Co., Inc.	2004	—	Designated
infliximab	infliximab	Centocor, Inc.	2002	—	Withdrawn
interferon Beta-1a	interferon Beta-1a	Biogen, Inc.	1998	—	Withdrawn
Purified type II collagen	Purified type II collagen	AutoImmune, Inc.	1995	—	Designated
Gammalinolenic acid	Gammalinolenic acid	Zurier, Robert B. M.D.	1994	—	Designated
methotrexate	methotrexate	Wyeth-Ayerst Laboratories	1993	—	Withdrawn
Immune globulin intravenous (human)	Immune globulin intravenous (human)	Immuno Clinical Research Corp.	1992	—	Withdrawn
Interleukin-1 receptor antagonist, human recombinant	Interleukin-1 receptor antagonist, human recombinant	Swedish Orphan Biovitrum AB (publ) (SOBI)	1991	—	Designated

Research Type	Count	% of Total
Research summaries	76	24%
Disease patterns and progression	72	22%
Clinical study results	51	16%
Laboratory research	43	13%
Testing and diagnosis research	41	13%
Patient case studies	27	8%
Other research	8	2%
New treatment approaches	4	1%

Kisho

juvenile idiopathic arthritis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real-World Care of Children with Juvenile Idiopathic Arthritis.

Probiotic supplementation increases fecal TLR4 agonists without improving disease activity in juvenile idiopathic arthritis: a randomized placebo-controlled trial.

Corrigendum to "Transition of serum-free IL-18 levels in systemic juvenile idiopathic arthritis measured by a novel detection method" [Cytokine 201 (2026) 157128].

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meeting

Arthritis Impacts African-Americans and Hispanics More than Whites

juvenile idiopathic arthritis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real-World Care of Children with Juvenile Idiopathic Arthritis.

Probiotic supplementation increases fecal TLR4 agonists without improving disease activity in juvenile idiopathic arthritis: a randomized placebo-controlled trial.

Corrigendum to "Transition of serum-free IL-18 levels in systemic juvenile idiopathic arthritis measured by a novel detection method" [Cytokine 201 (2026) 157128].

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meeting

Arthritis Impacts African-Americans and Hispanics More than Whites